Metropolis Healthcare Limited has announced the acquisition of Scientific Pathology, a diagnostic chain based in Agra, to strengthen its business-to-consumer (B2C) network in Western Uttar Pradesh. The acquisition, valued between ₹55 crore and ₹83 crore, will be executed through a business transfer agreement (BTA), with Metropolis taking over Scientific Pathology’s laboratories and collection centers.
Founded in 1984 by Dr. Ashok Kumar Sharma, Scientific Pathology operates three laboratories and 11 collection centers, two of which are NABL-accredited. The company reported a turnover of ₹26 crore in FY24, with 90% of its revenue coming directly from walk-in patients.
Ameera Shah, Promoter and Executive Chairwoman of Metropolis Healthcare, highlighted that the acquisition aligns with the company’s strategy of integrating regional diagnostic chains into its network. “Metropolis has completed over 20 acquisitions, integrating B2C laboratories in key cities and transforming them into regional hubs for expansion. This approach has helped us build strong consumer health brands across various micro-markets in India,” she said. She also emphasized that Scientific Pathology’s focus on B2C and its long-standing presence in the region are in sync with Metropolis’ vision. Dr. Sharma will continue to lead the team as part of the acquisition.
This move is part of a broader trend of consolidation in the Indian diagnostic sector, as larger players expand their reach and operational capabilities.
Surendran Chemmenkotil, CEO of Metropolis Healthcare, noted that Uttar Pradesh is a critical growth market, estimated to be worth ₹2,000 crore. “This acquisition is a strategic step in our plan to enhance our presence in the region and improve access to diagnostic services,” he said. Metropolis currently operates eight laboratories and over 80 franchise partners in Uttar Pradesh and aims to position Scientific Pathology as a regional reference laboratory. “By introducing our specialized test portfolio and expanding our structured franchise model, we aim to improve diagnostic accessibility across the region,” added Chemmenkotil.
Dr. Sharma expressed his confidence in the partnership, stating that it will enhance diagnostic capabilities in Agra and neighboring cities. “With Metropolis’ expertise and extensive test portfolio of over 4,000 tests, we will be able to deliver better healthcare services to patients,” he said.
The acquisition underscores Metropolis Healthcare’s commitment to expanding its footprint and improving diagnostic access in key regions across India.
